Literature DB >> 28760232

Biochemical Testing in Neuroendocrine Tumors.

Vidya Aluri1, Joseph S Dillon2.   

Abstract

Neuroendocrine cells are widely distributed throughout the body. They can produce, store, and secrete peptides and biogenic amines. Neuroendocrine tumors (NETs) are rare, but most are found in the intestine, pancreas, and lung. NETs may cause specific hormonal symptoms (eg, carcinoid syndrome) or appear nonfunctional. Blood or urine concentrations of tumor-secreted amines and peptides have been used as biomarkers in the diagnosis and management of NETs. This article focuses on currently available biochemical testing of blood or urine for gastroenteropancreatic and lung NETs and discusses the limitations of these tests and the potential role of newer multianalyte markers for NET management.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoid; Diagnostic test; Disease monitoring; Neuroendocrine tumor; Prognostic indicator; Tumor marker

Mesh:

Year:  2017        PMID: 28760232      PMCID: PMC5777173          DOI: 10.1016/j.ecl.2017.04.004

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  29 in total

1.  Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Pancreas       Date:  2012-05       Impact factor: 3.327

2.  Discriminating capacity of indole markers in the diagnosis of carcinoid tumors.

Authors:  W G Meijer; I P Kema; M Volmer; P H Willemse; E G de Vries
Journal:  Clin Chem       Date:  2000-10       Impact factor: 8.327

Review 3.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

4.  Serum peptide profiles in patients with carcinoid tumors.

Authors:  Kristine Calhoun; SuEllen Toth-Fejel; Julie Cheek; Rodney Pommier
Journal:  Am J Surg       Date:  2003-07       Impact factor: 2.565

5.  On the accurate determination of serotonin in human plasma.

Authors:  O Beck; N H Wallén; A Bröijersén; P T Larsson; P Hjemdahl
Journal:  Biochem Biophys Res Commun       Date:  1993-10-15       Impact factor: 3.575

6.  Chromogranin A: is it a useful marker of neuroendocrine tumors?

Authors:  Davide Campana; Francesca Nori; Lidya Piscitelli; Antonio Maria Morselli-Labate; Raffaele Pezzilli; Roberto Corinaldesi; Paola Tomassetti
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

7.  Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.

Authors:  G B Turner; B T Johnston; D R McCance; A McGinty; R G P Watson; C C Patterson; J E S Ardill
Journal:  Gut       Date:  2006-03-23       Impact factor: 23.059

8.  Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.

Authors:  C Lombard-Bohas; E Mitry; D O'Toole; C Louvet; D Pillon; G Cadiot; F Borson-Chazot; T Aparicio; M Ducreux; T Lecomte; P L Etienne; W Cacheux; J L Legoux; J F Seitz; P Ruszniewski; J A Chayvialle; P Rougier
Journal:  Neuroendocrinology       Date:  2008-08-22       Impact factor: 4.914

Review 9.  Molecular profiling for breast cancer: a comprehensive review.

Authors:  Muaiad Kittaneh; Alberto J Montero; Stefan Glück
Journal:  Biomark Cancer       Date:  2013-10-29

10.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

Authors:  Thierry Poynard; Françoise Imbert-Bismut; Mona Munteanu; Djamila Messous; Robert P Myers; Dominique Thabut; Vlad Ratziu; Anne Mercadier; Yves Benhamou; Bernard Hainque
Journal:  Comp Hepatol       Date:  2004-09-23
View more
  11 in total

1.  Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer.

Authors:  N V Lyubimova; A E Kuz'minov; A A Markovich; A V Lebedeva; Yu S Timofeev; I S Stilidi; N E Kushlinskii
Journal:  Bull Exp Biol Med       Date:  2022-06-23       Impact factor: 0.804

Review 2.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

3.  Chromogranin A Tubulopathy: Differing Histopathologic Patterns of Acute Tubular Injury in the Setting of Neuroendocrine Neoplasms.

Authors:  Miroslav Sekulic; Sushrut Waikar; Shveta S Motwani; Astrid Weins; Helmut G Rennke
Journal:  Kidney Int Rep       Date:  2019-05-08

4.  Surgical resection of pancreatic insulinoma during pregnancy: Case report and literature review.

Authors:  Carlos Castanha de Albuquerque Neto; Natália da Silva Lira; Marcelo A R C Albuquerque; Fernando Santa-Cruz; Laís de França M Vasconcelos; Álvaro A B Ferraz; Adriano C Costa
Journal:  Int J Surg Case Rep       Date:  2019-07-22

5.  Management of Diarrhea in Patients With Carcinoid Syndrome.

Authors:  Boris G Naraev; Magnus Halland; Daniel M Halperin; Amy J Purvis; Thomas M OʼDorisio; Thorvardur R Halfdanarson
Journal:  Pancreas       Date:  2019-09       Impact factor: 3.327

Review 6.  Management of Gastrointestinal Neuroendocrine Tumors.

Authors:  Rongzhi Wang; Rui Zheng-Pywell; H Alexander Chen; James A Bibb; Herbert Chen; J Bart Rose
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-10-24

Review 7.  Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review.

Authors:  Omid Yazdanpanah; Sarvani Surapaneni; Layla Shanah; Sohaip Kabashneh
Journal:  Cureus       Date:  2021-03-19

Review 8.  Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art.

Authors:  Jhean Gabriel Gonzáles-Yovera; Pela J Roseboom; Marcio Concepción-Zavaleta; Isamar Gutiérrez-Córdova; Esteban Plasencia-Dueñas; María Quispe-Flores; Anthony Ramos-Yataco; Carlos Alcalde-Loyola; Frederick Massucco-Revoredo; José Paz-Ibarra; Luis Concepción-Urteaga
Journal:  World J Methodol       Date:  2022-09-20

9.  Right and Left-Sided Carcinoid Heart Disease in the Setting of Selective Serotonin Reuptake Inhibitor Use.

Authors:  Jennifer Bell; Maad Alhudairy; Vera Kazakova; Michael Johnstone; Lana Tsao
Journal:  JACC Case Rep       Date:  2020-10-21

10.  Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.

Authors:  A Custodio; P Jimenez-Fonseca; A Carmona-Bayonas; M J Gomez; M I Del Olmo-García; I Lorenzo; J Á Díaz; N Canal; G De la Cruz; C Villabona
Journal:  Clin Transl Oncol       Date:  2021-06-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.